Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: A pilot trial demonstrating safety

Radiation Oncology

Volumn 8, Issue 1, 2013, Pages

  Gurka, Marie K ^a   Collins, Sean P ^a   Slack, Rebecca ^b,c   Tse, Gary ^a   Charabaty, Aline ^a   Ley, Lisa ^b   Berzcel, Liam ^b   Lei, Siyuan ^a   Suy, Simeng ^a   Haddad, Nadim ^a   Jha, Reena ^a   Johnson, Colin D ^d   Jackson, Patrick ^a   Marshall, John L ^b   Pishvaian, Michael J ^b  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

CyberKnife; Gemcitabine; Pancreatic cancer; QLQ C30; QLQ PAN26; Quality of life; Radiation; SBRT; Stereotactic body radiation therapy; Upper endoscopy

Indexed keywords

CAPECITABINE; ERLOTINIB; GEMCITABINE; LAPATINIB; VELIPARIB; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE;

ABDOMINAL CRAMP; ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER SIZE; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; CYBERKNIFE; DISTANT METASTASIS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DUODENUM MUCOSA; ENDOSCOPIC ECHOGRAPHY; ENDOSCOPY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HYPERTRANSAMINASEMIA; MALE; NAUSEA; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PILOT STUDY; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; QUESTIONNAIRE; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION INJURY; RADIATION SAFETY; STEREOTACTIC BODY RADIATION THERAPY; THERAPY DELAY; TREATMENT DURATION; TREATMENT RESPONSE; ADENOCARCINOMA; CLINICAL TRIAL; DISEASE COURSE; DOSE RESPONSE; DRUG ADMINISTRATION; METHODOLOGY; MIDDLE AGED; MORTALITY; PANCREAS TUMOR; RADIOSURGERY; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMORADIOTHERAPY; DEOXYCYTIDINE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PILOT PROJECTS; QUALITY OF LIFE; RADIOSURGERY; TREATMENT OUTCOME;

EID: 84874397634     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-8-44     Document Type: Article

References (45)

1. Moertel CG, Frytak S, Hahn RG, O'Connell MJ, Reitemeier RJ, Rubin J, Schutt AJ, Weiland LH, Childs DS, Holbrook MA. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 1981, 48:1705-1710. 10.1002/1097-0142(19811015)48:8<1705::AID-CNCR2820480803>3.0.CO;2-4, 7284971.
2. Moertel CG, Childs DS, Reitemeier RJ, Colby MY, Holbrook MA. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 1969, 2:865-867.
3. Gastrointestinal Tumor Study Group Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 1988, 80:751-755. Gastrointestinal Tumor Study Group.
4. Loehrer PJ, Feng Y, Cardenes H, Wagner L, Brell JM, Cella D, Flynn P, Ramanathan RK, Crane CH, Alberts SR, Benson AB. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol 2011, 29:4105-4112. 10.1200/JCO.2011.34.8904, 3525836, 21969502.
5. Chauffert B, Mornex F, Bonnetain F, Rougier P, Mariette C, Bouche O, Bosset JF, Aparicio T, Mineur L, Azzedine A. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol 2008, 19:1592-1599. 10.1093/annonc/mdn281, 18467316.
6. Klaassen DJ, MacIntyre JM, Catton GE, Engstrom PF, Moertel CG. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil-an Eastern Cooperative Oncology Group study. J Clin Oncol 1985, 3:373-378.
7. Yovino S, Poppe M, Jabbour S, David V, Garofalo M, Pandya N, Alexander R, Hanna N, Regine WF. Intensity-modulated radiation therapy significantly improves acute gastrointestinal toxicity in pancreatic and ampullary cancers. Int J Radiat Oncol Biol Phys 2011, 79:158-162. 10.1016/j.ijrobp.2009.10.043, 20399035.
8. Milano MT, Chmura SJ, Garofalo MC, Rash C, Roeske JC, Connell PP, Kwon OH, Jani AB, Heimann R. Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: toxicity and clinical outcome. Int J Radiat Oncol Biol Phys 2004, 59:445-453. 10.1016/j.ijrobp.2003.11.003, 15145161.
9. Feng M, Balter JM, Normolle D, Adusumilli S, Cao Y, Chenevert TL, Ben-Josef E. Characterization of pancreatic tumor motion using cine MRI: surrogates for tumor position should be used with caution. Int J Radiat Oncol Biol Phys 2009, 74:884-891. 10.1016/j.ijrobp.2009.02.003, 2691867, 19395190.
10. Horst E, Micke O, Moustakis C, Schuck A, Schafer U, Willich NA. Conformal therapy for pancreatic cancer: variation of organ position due to gastrointestinal distention-implications for treatment planning. Radiology 2002, 222:681-686. 10.1148/radiol.2223010639, 11867785.
11. Murphy JD, Chang DT, Abelson J, Daly ME, Yeung HN, Nelson LM, Koong AC. Cost-effectiveness of modern radiotherapy techniques in locally advanced pancreatic cancer. Cancer 2012, 118:1119-1129. 10.1002/cncr.26365, 21773972.
12. Koong AC, Christofferson E, Le QT, Goodman KA, Ho A, Kuo T, Ford JM, Fisher GA, Greco R, Norton J, Yang GP. Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2005, 63:320-323. 10.1016/j.ijrobp.2005.07.002, 16168826.
13. Schellenberg D, Goodman KA, Lee F, Chang S, Kuo T, Ford JM, Fisher GA, Quon A, Desser TS, Norton J. Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2008, 72:678-686. 10.1016/j.ijrobp.2008.01.051, 18395362.
14. Murphy JD, Christman-Skieller C, Kim J, Dieterich S, Chang DT, Koong AC. A dosimetric model of duodenal toxicity after stereotactic body radiotherapy for pancreatic cancer. Int J Radiat Oncol Biol Phys 2010, 78:1420-1426. 10.1016/j.ijrobp.2009.09.075, 20399033.
15. Murphy JD, Adusumilli S, Griffith KA, Ray ME, Zalupski MM, Lawrence TS, Ben-Josef E. Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2007, 68:801-808. 10.1016/j.ijrobp.2006.12.053, 17379445.
16. Rich T, Harris J, Abrams R, Erickson B, Doherty M, Paradelo J, Small W, Safran H, Wanebo HJ. Phase II study of external irradiation and weekly paclitaxel for nonmetastatic, unresectable pancreatic cancer: RTOG-98-12. Am J Clin Oncol 2004, 27:51-56. 10.1097/01.coc.0000046300.88847.BF, 14758134.
17. Mahadevan A, Jain S, Goldstein M, Miksad R, Pleskow D, Sawhney M, Brennan D, Callery M, Vollmer C. Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2010, 78:735-742. 10.1016/j.ijrobp.2009.08.046, 20171803.
18. Mahadevan A, Miksad R, Goldstein M, Sullivan R, Bullock A, Buchbinder E, Pleskow D, Sawhney M, Kent T, Vollmer C, Callery M. Induction gemcitabine and stereotactic body radiotherapy for locally advanced nonmetastatic pancreas cancer. Int J Radiat Oncol Biol Phys 2011, 81:e615-622. 10.1016/j.ijrobp.2011.04.045, 21658854.
19. Didolkar MS, Coleman CW, Brenner MJ, Chu KU, Olexa N, Stanwyck E, Yu A, Neerchal N, Rabinowitz S. Image-guided stereotactic radiosurgery for locally advanced pancreatic adenocarcinoma results of first 85 patients. J Gastrointest Surg 2010, 14:1547-1559. 10.1007/s11605-010-1323-7, 20839073.
20. Polistina F, Costantin G, Casamassima F, Francescon P, Guglielmi R, Panizzoni G, Febbraro A, Ambrosino G. Unresectable locally advanced pancreatic cancer: a multimodal treatment using neoadjuvant chemoradiotherapy (gemcitabine plus stereotactic radiosurgery) and subsequent surgical exploration. Ann Surg Oncol 2010, 17:2092-2101. 10.1245/s10434-010-1019-y, 20224860.
21. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247. 10.1016/j.ejca.2008.10.026, 19097774.
22. Kilby W, Dooley JR, Kuduvalli G, Sayeh S, Maurer CR. The CyberKnife robotic radiosurgery system in 2010. Technol Cancer Res Treat 2010, 9:433-452.
23. Pishvaian AC, Collins B, Gagnon G, Ahlawat S, Haddad NG. EUS-guided fiducial placement for CyberKnife radiotherapy of mediastinal and abdominal malignancies. Gastrointest Endosc 2006, 64:412-417. 10.1016/j.gie.2006.01.048, 16923491.
24. Spalding AC, Jee KW, Vineberg K, Jablonowski M, Fraass BA, Pan CC, Lawrence TS, Haken RK, Ben-Josef E. Potential for dose-escalation and reduction of risk in pancreatic cancer using IMRT optimization with lexicographic ordering and gEUD-based cost functions. Med Phys 2007, 34:521-529. 10.1118/1.2426403, 17388169.
25. Sun W, Leong CN, Zhang Z, Lu JJ. Proposing the lymphatic target volume for elective radiation therapy for pancreatic cancer: a pooled analysis of clinical evidence. Radiat Oncol 2010, 5:28. 10.1186/1748-717X-5-28, 2859771, 20398316.
26. Gaedcke J, Gunawan B, Grade M, Szoke R, Liersch T, Becker H, Ghadimi BM. The mesopancreas is the primary site for R1 resection in pancreatic head cancer: relevance for clinical trials. Langenbecks Arch Surg 2010, 395:451-458. 10.1007/s00423-009-0494-8, 2848727, 19418067.
27. Arvold ND, Niemierko A, Mamon HJ, Fernandez-del Castillo C, Hong TS. Pancreatic cancer tumor size on CT scan versus pathologic specimen: implications for radiation treatment planning. Int J Radiat Oncol Biol Phys 2011, 80:1383-1390. 10.1016/j.ijrobp.2010.04.058, 20708856.
28. Collins BT, Erickson K, Reichner CA, Collins SP, Gagnon GJ, Dieterich S, McRae DA, Zhang Y, Yousefi S, Levy E. Radical stereotactic radiosurgery with real-time tumor motion tracking in the treatment of small peripheral lung tumors. Radiat Oncol 2007, 2:39. 10.1186/1748-717X-2-39, 2174503, 17953752.
29. Wachter S, Gerstner N, Goldner G, Potzi R, Wambersie A, Potter R. Endoscopic scoring of late rectal mucosal damage after conformal radiotherapy for prostatic carcinoma. Radiother Oncol 2000, 54:11-19. 10.1016/S0167-8140(99)00173-5, 10719695.
30. Fitzsimmons D, Johnson CD, George S, Payne S, Sandberg AA, Bassi C, Beger HG, Birk D, Buchler MW, Dervenis C. Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer. EORTC Study Group on Quality of Life. Eur J Cancer 1999, 35:939-941. 10.1016/S0959-8049(99)00047-7, 10533475.
31. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
32. Nakamura JL, Verhey LJ, Smith V, Petti PL, Lamborn KR, Larson DA, Wara WM, McDermott MW, Sneed PK. Dose conformity of gamma knife radiosurgery and risk factors for complications. Int J Radiat Oncol Biol Phys 2001, 51:1313-1319. 10.1016/S0360-3016(01)01757-6, 11728692.
33. Ceha HM, Van Tienhoven G, Gouma DJ, Veenhof CH, Schneider CJ, Rauws EA, Phoa SS, Gonzalez Gonzalez D. Feasibility and efficacy of high dose conformal radiotherapy for patients with locally advanced pancreatic carcinoma. Cancer 2000, 89:2222-2229. 10.1002/1097-0142(20001201)89:11<2222::AID-CNCR10>3.0.CO;2-V, 11147592.
34. Fowler JF. Biological factors influencing optimum fractionation in radiation therapy. Acta Oncol 2001, 40:712-717. 10.1080/02841860152619124, 11765065.
35. Furukawa H, Iwata R, Moriyama N. Growth rate of pancreatic adenocarcinoma: initial clinical experience. Pancreas 2001, 22:366-369. 10.1097/00006676-200105000-00005, 11345136.
36. Roldan GE, Gunderson LL, Nagorney DM, Martin JK, Ilstrup DM, Holbrook MA, Kvols LK, McIlrath DC. External beam versus intraoperative and external beam irradiation for locally advanced pancreatic cancer. Cancer 1988, 61:1110-1116. 10.1002/1097-0142(19880315)61:6<1110::AID-CNCR2820610610>3.0.CO;2-6, 3342371.
37. Gunderson LL, Martin JK, Kvols LK, Nagorney DM, Fieck JM, Wieand HS, Martinez A, O'Connell MJ, Earle JD, McIlrath DC. Intraoperative and external beam irradiation +/- 5-FU for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 1987, 13:319-329. 10.1016/0360-3016(87)90005-8, 3104244.
38. Mohiuddin M, Regine WF, Stevens J, Rosato F, Barbot D, Biermann W, Cantor R. Combined intraoperative radiation and perioperative chemotherapy for unresectable cancers of the pancreas. J Clin Oncol 1995, 13:2764-2768.
39. Garton GR, Gunderson LL, Nagorney DM, Donohue JH, Martin JK, McIlrath DC, Cha SS. High-dose preoperative external beam and intraoperative irradiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 1993, 27:1153-1157. 10.1016/0360-3016(93)90537-6, 8262841.
40. Shipley WU, Nardi GL, Cohen AM, Ling CC. Iodine-125 implant and external beam irradiation in patients with localized pancreatic carcinoma: a comparative study to surgical resection. Cancer 1980, 45:709-714. 10.1002/1097-0142(19800215)45:4<709::AID-CNCR2820450416>3.0.CO;2-5, 6244074.
41. Shipley WU, Tepper JE, Warshaw AL, Orlow EL. Intraoperative radiation therapy for patients with pancreatic carcinoma. World J Surg 1984, 8:929-934. 10.1007/BF01656034, 6516433.
42. Mohiuddin M, Cantor RJ, Biermann W, Weiss SM, Barbot D, Rosato FE. Combined modality treatment of localized unresectable adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys 1988, 14:79-84. 10.1016/0360-3016(88)90054-5, 3121546.
43. Lawrence TS, Chang EY, Hahn TM, Hertel LW, Shewach DS. Radiosensitization of pancreatic cancer cells by 2',2'-difluoro-2'-deoxycytidine. Int J Radiat Oncol Biol Phys 1996, 34:867-872. 10.1016/0360-3016(95)02134-5, 8598364.
44. McGinn CJ, Zalupski MM, Shureiqi I, Robertson JM, Eckhauser FE, Smith DC, Brown D, Hejna G, Strawderman M, Normolle D, Lawrence TS. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2001, 19:4202-4208.
45. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011, 364:1817-1825. 10.1056/NEJMoa1011923, 21561347.